What African Healthtech Innovators Need to Know About Valuation in 2026 

As the funding environment contracts, valuations have followed. Investors warn that multiples for African healthcare businesses have compressed in the last 5 years: where EBITDA multiples for African healthcare businesses reached 12-16x, today 6-10x is more common. In this environment, how should founders be thinking about valuation? 

To unpack the challenge, in April i3 convened a valuation learning session with 20 leading healthtech executives and 3 experts: Rajal Upadhyaya (30+ years advising, investing in, and operating businesses across Africa; founding investor and former board member at GoodLife Pharmacy), Zakir Mohammed (Legal Counsel at Impact Fund Denmark, Denmark's development finance institution), and Amaan Khalfan (i3 deal expert, former CEO of GoodLife Pharmacy). 5 key takeaways emerged: 

1. Capital has shifted from growth-at-all-costs to value generation 

This is one of the hardest times to raise capital. Investor appetite has moved from growth-at-all-costs venture models toward businesses with solid fundamentals, quality revenue, and strong governance. Investors now want evidence of all three. Thenotion of patient, concessional DFI capital is receding. DFIs have shifted toward commercial targets with return obligations to investors beyond the state. Strategic investors remain active in healthcare but are disciplined and longer-term. For founders, the implication is that while growth still matters, growth without evidence of value creation carries less weight now. 

2. Quality of earnings beats top-line growth 

For growth-stage companies, investors scrutinize customer concentration, the share of recurring versus one-off revenue, the split between government and private sector buyers, and defensibility against better-funded entrants. For pre-profit companies, the conversation moves to the path to profitability. A 12-to-18-month path is credible. A 36-to-48-month path raises the question of who funds the gap and how existing investors get diluted. 

3. Trust is the most valuable asset to build 

Fundraising is a partnership, and trust is the foundation. That trust is built through repeated, consistent communication over time. Tell an investor what you will achieve in 6 months. Come back and report what you did, what you missed, and why. One company closed a round with an investor who first issued a term sheet 2.5 years earlier. They politely declined, kept the investor updated, and came back when the timing was right. The deal moved fast because trust was already in place. Investor alignment matters too. The cheapest capital could become the most expensive if the investor is misaligned on vision, pace, or control. Ask the hard questions before signing. What value will this investor add in tough times? How do they align with your strategy? Investors respect founders who engage with clarity on these points. It signals confidence in what you are building. 

4. Good governance is critical to reinforcing a sense of trust – it’s not just a checkbox 

Weak governance is one of the most common reasons deals fall apart. Investors look for a nimble but expert board, clean cap tables, financial discipline that ties capital to its intended use, and reporting infrastructure that can absorb institutional investor requirements.  

5. Your impact pitch and your commercial pitch should be the same pitch 

A common question founders face is whether to lead with impact or commercials when speaking to investors. The answer from the session was clear: they should not be separate conversations. A commercially sustainable business reaching the last mile in African healthcare will produce impact inherently. Splitting them into two framings signals to investors that the business model does not stand on its own. Founders who walk into a room with one integrated story, where the commercial engine drives the impact outcome, are better positioned to attract and retain institutional capital.  

Meet the Leading Innovators Shaping the Future of Pharmacy in Africa

In Africa, the need for locally-driven, sustainable solutions to bring health products to people has never been greater. Leading Future of Pharmacy startups operating in 19 countries across the continent are tackling this challenge head-on and advancing innovations that are expanding patient access, lowering costs and increasing visibility.

Thanks to the support of the Gates Foundation, MSD, Cencora, Endless Foundation, HELP Logistics, Sanofi’s Global Health Unit, and Boehringer Ingelheim, these companies are proving how powerful, tech-enabled solutions can result in more efficient, data-driven delivery at scale—improving patient outcomes and spurring economic growth in the process.

To explore the work of this remarkable cohort—including deeper insights into their business models, customer reach, and strategic partners—check out our newly released i3 Future of Pharmacy Cohort Lookbook and see how they’re making essential care more accessible, affordable, and safer. 

Please share widely with your networks and don’t hesitate to reach out to us at support@innovationsinafrica.com if you'd like us to make a connection on your behalf.

i3 Calls for Applicants to 3rd Cohort for Program Enabling African Healthtech Innovators to Commercialise & Scale Offerings

UPDATE, January 28, 2025. On Jan 25th, the US government issued a ‘stop work’ directive for US aid, intensifying the need for locally-driven, market-creating approaches to health product distribution and service delivery across Africa. In response, i3 has taken the decision to prioritize immediate support for 5-7 growth-stage companies building the Future of Pharmacy care in Africa, increasing efforts to help these innovative companies rapidly expand access to patient care. Thus, i3 is only selecting growth-stage companies focused on the Future of Pharmacy at this time. We aim to support to a set of early-stage companies at a later date. Please sign up for our newsletter to stay in touch.
January 27, 2025, Lagos, Nigeria - Investing in Innovation Africa (i3), a pan-African initiative to support African healthtech startups to commercialise and scale their offerings, is calling for leading innovators to join its 3rd cohort. Funded by the Gates Foundation, MSD, Cencora, Endless Foundation, HELP Logistics–a subsidiary of the Kühne Foundation, Sanofi’s Global Health Unit and Chemonics, i3 will offer select startups 3 critical resources to prepare themselves for expansion: flexible grants, introductions to potential customers and tailored counsel to close partnership deals. i3 is selecting a total of 15 leading startups for this cohort: Early-stage startups will receive a $50K grant and growth-stage startups will receive a $225K grant to unlock major partnerships that can expand patient access across the continent. For startups in the cohort, i3 aims to facilitate at least 150 relationships with key healthcare organizations, worth at least $30M, which will expand patient access while creating valuable local jobs. Applications for the 3rd cohort are open now until February 28th. Apply here: innovationsinafrica.com/application. The selected startups will be announced on April 30th. In just two years since its launch, i3 has empowered 60 African health innovators across 16 countries, exceeding expectations with 43% women-led and 20% Francophone-led ventures. The program provided $3M in direct grants, facilitated 450 strategic connections, resulting in >$11M in contracted partnerships, expanded reach, and nearly 1,000 jobs created—half of which were held by women. Dr. Uchenna Igbokwe, CEO, SCIDaR “With the right resources, African-led companies can scale commercially while reaching underserved communities and creating jobs. The i3 program has been able to prove, in just two years, that an actively engaged network of leading global health institutions and partners can power African innovators to solve critical African problems in healthcare.” Oghenetega Iortim, CEO of Figorr, a company that provides end-to-end supply chain tracking technology and an i3 alumni, said, “We partnered with the Nigerian government to track over 200M health products. Through i3 we met with major global customers who were excited to find ways to expand Figorr’s impact both in Nigeria, and beyond. We’re grateful to i3 for opening these doors.” Applications for the 3rd cohort are open now until February 28. Apply here: innovationsinafrica.com/application. The selected startups will be announced on April 30th. A virtual Q&A session will be hosted by i3 on February 21st to answer any questions regarding the application process. i3 is coordinated by Salient Advisory and Solina Center for International Development and Research (SCIDaR).

Advancing African Healthtech: Join the Investing in Innovation Program at UNGA 79 

As the 79th United Nations General Assembly (UNGA 79) convenes, global leaders, donors, and innovators are united in addressing the world's most pressing challenges. This year’s focus on collaboration is crucial to driving progress, particularly in healthcare, where African-led innovations are laying the groundwork for a sustainable future. 

The Investing in Innovation (i3) program is a proven model of how healthtech innovation can drive sustainable development. In the last two years, i3 was Africa’s most active healthtech funder, supporting 60 African-led companies focused on supply chain solutions. We facilitated 450+ introductions between innovators and key customers—including donors, governments, and industries—leading to 122 MOUs, pilot projects, and partnerships worth over $11M dollars. Nearly 50 innovators expanded into new geographies, collectively raising an additional $50 million and creating 942 jobs, with nearly half held by women.  

To scale this impact, we are calling on donors, global health institutions, and governments at UNGA 79 to evolve their aid systems. Now is the time to test a new model of development aid—one that generates sustainable impact, creates local jobs, and advances gender equality in the health sector.

Key Messages & Call to Action 

  1. Global aid systems must move beyond traditional frameworks and embrace local, data-driven innovations to achieve meaningful, long-term impact. By partnering with African-led healthtech startups, donors and governments can support sustainable solutions that are embedded in local markets and address the continent's most critical healthcare challenges. Measurably increase your engagement with African healthtech innovators. 
  1. Despite the potential, global health institutions and donors have not typically engaged deeply with local innovators. This must change. African healthtech startups, like those supported by i3, are already demonstrating significant impact—i3 innovators have enabled over 198 million lives—but they need broader support to scale their efforts. Institutions must adapt their processes to contract more innovative local companies and invest ambitiously in tech-driven service delivery innovations, alongside local manufacturing. 

Only by pursuing an ambitious vision for building more effective health markets will we succeed. Join us as champions of African healthtech as we "put the S in the SDGs!” 


The i3 team and CEOs from leading i3 innovators Figorr, Chefaa, Kapsule, and more will be at these key events at UNGA 79:  

If you're attending and would like to meet with our team or any of the exceptional innovators, please get in touch! We would love to share more.  

Advancing African Healthtech — Meet i3 at WHA 77 in Geneva 

Over the last 21 months Investing in Innovation (i3) has supported 60 African-led innovations in supply chain with $50K USD in grant funding and over 450 bespoke introductions to major public health customers. Nearly half of i3 startups are led by women, underscoring our commitment to supporting diverse leadership in the health sector. 

The i3 team, alongside the CEOs of Figorr and Kapsule, will be in Geneva alongside the 77th World Health Assembly (WHA) to shine a spotlight on African-led innovation in healthtech, and advocate for a new model of collaboration between industry, aid, and innovators to advance product access. We have 3 key messages for the global community:  

i3 will participate in two key spotlight events and hold one-on-one sessions.  

i3 Innovation Dinner with Global Health Leaders and Innovators: We are hosting a small, invitation only Innovation Dinner on May 28th, bringing together leaders from governments, global health agencies, industry, and donors to build relationships, share information, and advance the impact of African-led healthtech. We will spotlight two i3 innovators – Figorr and Kapsule. 

Panel at Devex Checkup @WHA 77: Scaling Health Innovations in Africa: On May 29, we will be featured in a panel discussion at the Devex Checkup event titled "From spark to scale: Supporting Africa's booming health innovation landscape." The session will highlight lessons from i3’s efforts to support 60 promising companies leveraging technology to optimize supply chains and address challenges of availability, accessibility, and affordability of health products in Africa. The panelists include David Chen, co-CEO, Kapsule; Oghenetega Iortim, CEO, Figorr; and Mara Hansen Staples, Founder, Salient Advisory. You can register for onsite or virtual participation here.  

In addition, i3 is arranging one-on-one meetings throughout WHA 77. If you're attending and would like to meet with our team, Kapsule or Figorr, please get in touch. We would love to share more. 

We look forward to building partnerships that will continue to scale health innovations and create lasting impacts in Africa. Join us! 

Discover Figorr — The Health Supply Chain Innovator Saving Lives in Nigeria and Beyond

Discover how Figorr, a young Nigerian startup in the i3 program, is revolutionizing Africa's health supply chains with its groundbreaking MOTE device. They grew rapidly amidst the COVID-19 pandemic, and now track all of Nigeria’s EPI and COVID-19 vaccines in partnership with the National Primary Healthcare Development Agency, helping them prevent wastage and protect millions of lives. On the back of its success in Nigeria, Figorr expanded to eight other countries, and has tracked nearly 200 million health products.

Figorr exemplifies the type of African-led innovation i3 is passionate about supporting—solutions that are ingenious, sustainable, and pave the way for a healthier, more resilient Africa. And Figorr is not alone—at i3, we have selected and supported 60 leading healthtech companies working to expand access, and connect them to customers seeking high-impact, scalable routes to market. Collectively, these innovators reach over 32K providers across the continent, touching an estimated 150M patient visits annually. If you’re interested in connecting with leading African healthtech innovators to advance your reach and impact, please get in touch.

Together with The Bill & Melinda Gates Foundation, Cencora, Chemonics, MSD & Microsoft, we celebrate the power of African-led innovation and our joint commitment to fostering sustainable, resilient supply chains around the world. Join us!

I3 is implemented by Salient Advisory and SCIDaR, and leading accelerator partners; Villgro Africa, CcHub, IMPACT Lab and StartupBootCamp AfriTech.